Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:EWTX NASDAQ:IMCR NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.38-3.2%$14.87$12.79▼$55.70$1.62B1.031.80 million shs600,794 shsEWTXEdgewise Therapeutics$15.09-1.7%$14.49$10.60▼$38.12$1.59B0.281.17 million shs136,923 shsIMCRImmunocore$34.31+0.9%$33.67$23.15▼$39.33$1.73B0.79329,706 shs45,118 shsUPXIUpexi$7.12-7.6%$6.41$1.90▼$22.57$414.00M-0.534.03 million shs3.74 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+0.59%+8.51%+0.49%+14.60%-66.55%EWTXEdgewise Therapeutics-1.92%-2.54%-1.41%+17.90%-45.95%IMCRImmunocore-0.58%-0.96%-8.58%+2.19%+9.32%UPXIUpexi+3.49%+37.01%+27.48%+86.44%+229.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.38-3.2%$14.87$12.79▼$55.70$1.62B1.031.80 million shs600,794 shsEWTXEdgewise Therapeutics$15.09-1.7%$14.49$10.60▼$38.12$1.59B0.281.17 million shs136,923 shsIMCRImmunocore$34.31+0.9%$33.67$23.15▼$39.33$1.73B0.79329,706 shs45,118 shsUPXIUpexi$7.12-7.6%$6.41$1.90▼$22.57$414.00M-0.534.03 million shs3.74 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+0.59%+8.51%+0.49%+14.60%-66.55%EWTXEdgewise Therapeutics-1.92%-2.54%-1.41%+17.90%-45.95%IMCRImmunocore-0.58%-0.96%-8.58%+2.19%+9.32%UPXIUpexi+3.49%+37.01%+27.48%+86.44%+229.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.00Buy$48.85217.70% UpsideEWTXEdgewise Therapeutics 2.69Moderate Buy$38.83157.41% UpsideIMCRImmunocore 2.33Hold$56.8965.83% UpsideUPXIUpexi 2.67Moderate Buy$15.50117.79% UpsideCurrent Analyst Ratings BreakdownLatest UPXI, IMCR, BHVN, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025BHVNBiohavenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025EWTXEdgewise TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMCRImmunocoreWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025UPXIUpexiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025EWTXEdgewise TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$20.009/24/2025EWTXEdgewise TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/18/2025IMCRImmunocoreGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral9/17/2025BHVNBiohavenCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/16/2025BHVNBiohavenUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $26.009/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy ➝ Strong-Buy(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/AIMCRImmunocore$310.20M5.57N/AN/A$7.20 per share4.76UPXIUpexi$15.81M26.51N/AN/A$1.01 per share7.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)IMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)UPXIUpexi-$13.68MN/A0.00∞N/A-86.54%-54.33%-31.28%N/ALatest UPXI, IMCR, BHVN, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.913.823.82EWTXEdgewise TherapeuticsN/A28.8728.87IMCRImmunocore1.015.895.86UPXIUpexiN/A1.741.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%EWTXEdgewise TherapeuticsN/AIMCRImmunocore84.50%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%EWTXEdgewise Therapeutics23.20%IMCRImmunocore10.40%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239105.79 million90.35 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableUPXI, IMCR, BHVN, and EWTX HeadlinesRecent News About These CompaniesUpexi to Participate in Upcoming October Investor ConferencesOctober 6 at 10:17 AM | markets.businessinsider.comUpexi, Inc. to Participate in Multiple Investor Conferences in October 2025October 6 at 8:31 AM | quiverquant.comQUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestOctober 4 at 3:36 PM | marketbeat.comUpexi adds SOL Big Brain to advisory committeeSeptember 30, 2025 | msn.comUpexi Welcomes SOL Big Brain to the Upexi Advisory CommitteeSeptember 30, 2025 | markets.businessinsider.comKathmere Capital Management LLC Makes New Investment in Upexi, Inc. $UPXISeptember 27, 2025 | marketbeat.comUpexi (UPXI) Expected to Announce Earnings on MondaySeptember 25, 2025 | marketbeat.comUpexi Inc: Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 25, 2025 | finanznachrichten.deUpexi, Inc. Reports Financial Results for Fiscal Year 2025 and Provides Update on Solana Treasury PerformanceSeptember 24, 2025 | quiverquant.comQUpexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 24, 2025 | globenewswire.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateSeptember 15, 2025 | marketbeat.comUpexi Stock Pops Pre-Market, Retail Chatter Surges On Growing Solana Treasury HoldingsSeptember 12, 2025 | msn.comUpexi's Stellar Gains: Solana Treasury Strategy Drives 129% Growth in SOL ValueSeptember 12, 2025 | econotimes.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)September 11, 2025 | prnewswire.comUpexi Adjusted SOL per Share Increases 129% Since Treasury LaunchSeptember 11, 2025 | globenewswire.comSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8, 2025 | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Stock Price Down 4.5% - What's Next?September 7, 2025 | marketbeat.comUpexi to Participate in Upcoming September ConferencesSeptember 3, 2025 | manilatimes.netMBitcoin Gains As ‘September Slump’ Remains Uncertain – Retail Traders Bet On Break From Trend In 2025September 3, 2025 | msn.comUpexi, Inc. Announces Strategic Investment in Alpha ExchangeAugust 28, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPXI, IMCR, BHVN, and EWTX Company DescriptionsBiohaven NYSE:BHVN$15.38 -0.51 (-3.18%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Edgewise Therapeutics NASDAQ:EWTX$15.09 -0.26 (-1.72%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Immunocore NASDAQ:IMCR$34.30 +0.30 (+0.87%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Upexi NASDAQ:UPXI$7.12 -0.58 (-7.57%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
